Lupin unveils Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution in US

The product is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

Published On 2022-09-09 06:57 GMT   |   Update On 2022-09-09 06:57 GMT
Advertisement

Mumbai: Pharma major, Lupin Limited, today announced the launch of Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces, having received an approval from the United States Food and Drug Administration (USFDA).

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces is a generic equivalent of Suprep Bowel Prep Kit Oral Solution, 17.5 g/3.13 g/1.6 g per 6 ounces, of Braintree Laboratories Inc.

Advertisement

Read also: Lupin to acquire diabetes brands Ondero, Ondero-Met from Boehringer Ingelheim for Rs 207 crore   

The product is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.  

Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Oral Solution (RLD Suprep Bowel Prep Kit) had estimated annual sales of USD 202 million in the U.S. (IQVIA MAT July 2022).   

Read also: Lupin, DKSH ink pact to commercialize 5 of Alvotech proposed biosimilars in Philippines 

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company was founded by Desh Bandhu Gupta in 1968. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.    
The company invested 8.7% of its revenue in research and development in FY22. Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.   
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News